Strs Ohio Raises Holdings in GRAIL, Inc. $GRAL

Strs Ohio boosted its position in GRAIL, Inc. (NASDAQ:GRAL) by 95.3% during the first quarter, Holdings Channel.com reports. The fund owned 16,600 shares of the company’s stock after purchasing an additional 8,100 shares during the quarter. Strs Ohio’s holdings in GRAIL were worth $858,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in GRAL. Perigon Wealth Management LLC increased its stake in GRAIL by 0.7% during the fourth quarter. Perigon Wealth Management LLC now owns 19,450 shares of the company’s stock worth $1,665,000 after acquiring an additional 133 shares during the last quarter. Parallel Advisors LLC lifted its stake in shares of GRAIL by 5.2% in the 4th quarter. Parallel Advisors LLC now owns 2,667 shares of the company’s stock valued at $228,000 after purchasing an additional 133 shares in the last quarter. Westmount Partners LLC lifted its stake in shares of GRAIL by 1.8% in the 4th quarter. Westmount Partners LLC now owns 8,279 shares of the company’s stock valued at $709,000 after purchasing an additional 150 shares in the last quarter. Comerica Bank grew its holdings in shares of GRAIL by 59.2% during the 3rd quarter. Comerica Bank now owns 465 shares of the company’s stock worth $27,000 after purchasing an additional 173 shares during the period. Finally, Whittier Trust Co. grew its holdings in shares of GRAIL by 19.3% during the 4th quarter. Whittier Trust Co. now owns 1,114 shares of the company’s stock worth $95,000 after purchasing an additional 180 shares during the period.

Analyst Ratings Changes

Several equities research analysts have issued reports on GRAL shares. The Goldman Sachs Group began coverage on shares of GRAIL in a research note on Friday, June 5th. They set a “neutral” rating and a $60.00 price objective for the company. Wolfe Research began coverage on shares of GRAIL in a report on Tuesday, June 2nd. They set a “peer perform” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GRAIL in a research report on Tuesday, April 21st. Mizuho assumed coverage on GRAIL in a research report on Friday, April 10th. They issued a “neutral” rating and a $58.00 price objective on the stock. Finally, Guggenheim cut their price objective on GRAIL from $130.00 to $75.00 and set a “buy” rating on the stock in a research report on Monday, March 30th. Four equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $67.00.

More GRAIL News

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: GRAIL shares are drawing buying interest despite the lawsuit headlines, suggesting some traders may be focusing on the stock’s volatility and potential for a rebound. Article Title
• Neutral Sentiment: Several firms, including Rosen, Faruqi & Faruqi, Pomerantz, Levi & Korsinsky, and others, are reminding investors of the August 4 lead-plaintiff deadline in the pending class action. Article Title
• Neutral Sentiment: The class action itself appears to be focused on alleged investor harm tied to the February 20 trial disclosure and the period from May 13, 2025 through February 19, 2026. Article Title
• Negative Sentiment: The repeated legal notices reinforce a significant litigation overhang and keep attention on the earlier $2.2 billion market-cap wipeout, which can weigh on sentiment toward GRAL. Article Title

GRAIL Stock Performance

GRAL opened at $70.14 on Thursday. The company has a market capitalization of $3.01 billion, a P/E ratio of -6.76 and a beta of 3.22. The company has a 50-day moving average of $63.37 and a 200-day moving average of $70.11. GRAIL, Inc. has a 1-year low of $29.95 and a 1-year high of $118.84.

GRAIL (NASDAQ:GRAL) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($2.29) EPS for the quarter, topping analysts’ consensus estimates of ($2.76) by $0.47. The business had revenue of $40.78 million during the quarter, compared to the consensus estimate of $39.16 million. GRAIL had a negative return on equity of 16.42% and a negative net margin of 253.22%. As a group, sell-side analysts expect that GRAIL, Inc. will post -10.91 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Andrew John Partridge sold 1,491 shares of GRAIL stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $61.08, for a total value of $91,070.28. Following the completion of the transaction, the insider owned 163,738 shares in the company, valued at approximately $10,001,117.04. This trade represents a 0.90% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.83% of the stock is currently owned by corporate insiders.

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.